JCO2Rec'd PCT/PTC 2 5 JUN 2001 Atty. Docket No. Serial No.: N Form PTO-1449 **U.S. Department of Commerce** (Rev. 2-32) Patent & Trademark Office Q64929 Confirmation N INFORMATION DISCLOSURE STATEMENT Applicant: Shohei TANAKA, et al. (Use several sheets if necessary) Filing Date: Group: June 25, 2001 Not Yet Assigned U.S. PATENT DOCUMENTS Examiner Document Number Date Name Class Sub-Initial Filing Date Class (if appropriate) SM 4,990,503 02/05/91 ISOMURA ET AL 514 80 FOREIGN PATENT DOCUMENTS Document Date Country Class Sub-Translation class Yes/No 99/04773 02/04/99 WIPO A61K 31/00 95/28936 11/02/95 WIPO A61K 31/675 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Berenson, J.R., Bisphosphonates in Multiple Myeloma. Cancer (New York), 1997, Vol.80, No.8 (Supplement), 51 pages 1661-1667. V Claire M. Shipman, et al. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. British Journal of Haematology 1997. Vol. 98. pages 665-672. C. Roux et al. Biologic, Histologic and Densitometric Effects of Oral Risedronate on Bone in Patients with Multiple Myeloma. Bone, Vol.15, No. 1, pp 41-49, 1994. Claire M. Shipman, et al. Anti-Tumour Activity of Bisphosphonates In Human Myeloma Cells. Leukemia and Lymphoma, 1998, Vol 32(1-2)pp. 129-138. Madhav V. Dhodapkar, et al. Anti-myeloma activity of pamidronate in vivo. British Journal of Haematology, 84

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if **EXAMINER:** not in conformance and not considered. Include copy of this form with next communication.

DATE CONSIDERED:

1998. Vol 103, pages 530-532. V

EXAMINER: